Skip to main content
Journal cover image

Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.

Publication ,  Journal Article
Krug, LM; Crawford, J; Ettinger, DS; Shapiro, GI; Spigel, D; Reiman, T; Temel, JS; Michelson, GC; Young, DY; Hoch, U; Adelman, DC
Published in: J Thorac Oncol
February 2011

INTRODUCTION: Voreloxin is an anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, causing double-strand breaks in DNA, irreversible G2 arrest, and rapid onset of apoptosis. Based on preclinical activity of voreloxin in chemoresistant tumors, early phase I clinical activity, and a mechanism of action similar to other topoisomerase II inhibitors such as the anthracyclines and etoposide, this phase II trial was undertaken as second-line treatment of small cell lung cancer (SCLC). METHODS: Patients with extensive stage SCLC previously treated with one prior chemotherapy regimen were eligible. Patients with chemotherapy-sensitive or chemotherapy-refractory disease were considered as separate cohorts. Voreloxin (48 mg/m) was administered on the first day of each 21-day cycle for up to six cycles. The primary end point was objective response rate. RESULTS: Fifty-five patients were enrolled including 28 with refractory SCLC and 27 with sensitive SCLC; 47 were evaluable for response. Three patients with sensitive SCLC had an objective response, including one complete response and two partial responses (11% response rate based on intent to treat). No patients in the refractory cohort had a response. The primary grade 3 toxicity was neutropenia. CONCLUSION: Voreloxin has minimal activity in relapsed SCLC when administered at 48 mg/m in a 3-week schedule.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

February 2011

Volume

6

Issue

2

Start / End Page

384 / 386

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thiazoles
  • Survival Rate
  • Small Cell Lung Carcinoma
  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Naphthyridines
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Krug, L. M., Crawford, J., Ettinger, D. S., Shapiro, G. I., Spigel, D., Reiman, T., … Adelman, D. C. (2011). Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol, 6(2), 384–386. https://doi.org/10.1097/JTO.0b013e318200e509
Krug, Lee M., Jeffrey Crawford, David S. Ettinger, Geoffrey I. Shapiro, David Spigel, Tony Reiman, Jennifer S. Temel, et al. “Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.J Thorac Oncol 6, no. 2 (February 2011): 384–86. https://doi.org/10.1097/JTO.0b013e318200e509.
Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, et al. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol. 2011 Feb;6(2):384–6.
Krug, Lee M., et al. “Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.J Thorac Oncol, vol. 6, no. 2, Feb. 2011, pp. 384–86. Pubmed, doi:10.1097/JTO.0b013e318200e509.
Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol. 2011 Feb;6(2):384–386.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

February 2011

Volume

6

Issue

2

Start / End Page

384 / 386

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thiazoles
  • Survival Rate
  • Small Cell Lung Carcinoma
  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Naphthyridines
  • Middle Aged
  • Male